Thu, March 15, 2012
Wed, March 14, 2012
Tue, March 13, 2012
Mon, March 12, 2012
Sat, March 10, 2012
Fri, March 9, 2012
Thu, March 8, 2012
Wed, March 7, 2012
Tue, March 6, 2012
[ Tue, Mar 06th 2012 ]: Market Wire
Verotoxin and E. coli 0157
Mon, March 5, 2012
[ Mon, Mar 05th 2012 ]: Market Wire
Sienna Gold Warrants Extended
[ Mon, Mar 05th 2012 ]: Market Wire
30 a.m. ET
Fri, March 2, 2012

Regeneron Announces Change in Date for Presentation at Barclays Capital 2012 Global Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. s-capital-2012-global-healthcare-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation



Regeneron Announces Change in Date for Presentation at Barclays Capital 2012 Global... -- TARRYTOWN, N.Y., March 9, 2012 /PRNewswire/ --

Regeneron Announces Change in Date for Presentation at Barclays Capital 2012 Global Healthcare Conference

[ ]

TARRYTOWN, N.Y., March 9, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: [ REGN ]) will webcast its presentation at Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13, 2012 at 3:45 p.m. Eastern Time. The March 13, 2012 date is a change from the previously announced date of March 14, 2012 and is due to conference rescheduling.

The session may be accessed through the Company's web site, [ www.regeneron.com ], on the Events and Presentations page.  An archived version of the presentation will be available for thirty days after the live webcast. 

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition.  Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development. More information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Contact Information:

 

 

 

Manisha Narasimhan, Ph.D.

Peter Dworkin

Investor Relations

Corporate Communications                           

914-847-5126

914-847-7640            

[ manisha.narasimhan@regeneron.com ]

[ peter.dworkin@regeneron.com ]

SOURCE Regeneron Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear